 [-96 (-159, -32) 
Introduction
shown that acute suppression of sex hormones reduces REE below mid-luteal and earlyfollicular levels (5). 66
A limitation of our previous study was that sex hormones were suppressed for 67 only 6 days (5). The effects of more chronic suppression (e.g., months) are not known. 68
We also did not previously determine if the reduction in REE was specifically due to the 69 decrease in E 2 . Furthermore, it is not known if sex hormone suppression affects 70 components of total daily EE (e.g., thermic effect of feeding, EE of exercise, and non-71 exercise EE) other than REE. In this context, the primary aim of this study was to 72 determine in premenopausal women the effects of chronic sex hormone suppression on 73 total EE (TEE) and its components. The secondary aim was to determine if the 74 decrease in EE is mediated by the loss of circulating E 2 . Participants underwent 5 75 months of gonadotropin releasing hormone agonist (GnRH AG ) therapy to chronically 76 suppress ovarian hormones, and were randomized to receive placebo or E 2 add-back 77 therapy. TEE and its components were assessed before and after the intervention 78 using whole-room indirect calorimetry. We hypothesized that TEE and its components 79 would be reduced by chronic sex hormone suppression, and that these decreases 80 would be attenuated by E 2 therapy. Based on previous research, we anticipated that 5 81 
Exercise intervention to stabilize body composition 191
Based on previous research, we anticipated that 5 months of GnRH AG +PL 192 therapy would cause a decrease in FFM of ~1.0 kg and an increase in fat mass of ~1.5 193 kg after 5 mo of therapy (6, 32, 44) . This decrease in FFM would be expected to 194 augment the reduction in REE related to E 2 suppression (14). As an exploratory aim, 195 some participants in each drug group were also randomized to take part in a 196 progressive resistance exercise training program (GnRH AG +E 2 +Ex; GnRH AG +PL+Ex). 197
The progressive resistance exercise intervention began in week 1 of sex hormone 198 suppression, and was performed 4 d/wk for 18 weeks, as has been previously 199 described (34). The exercise program was stopped 2 wk prior to follow-up testing to 200 minimize the acute effects of exercise on the study outcomes. 201 during week 20 of the intervention. Collection samples were stored at -80°C until 205 analysis. Estrone (E 1 ), E 2 , and progesterone (P) were determined by 206 radioimmunoassay (RIA, Diagnostic Systems Lab, Webster, TX). Respective intra-and 207 inter-assay CVs were 8.7% and 8.6% for E 1 , 6% and 11% for E 2 , and 7.5% and 10.2% 
Statistical analysis 214
The primary analysis compared the GnRH AG +E 2 and GnRH AG +PL groups, pooled 215 across exercise status. Baseline differences in all variables between the GnRH AG +E 2 216
and GnRH AG +PL groups were evaluated using two-group t tests. Changes within each 217 group in response to intervention were also evaluated with paired t tests. Differences in 218 change over time between groups were tested using an ANCOVA model, first with 219 treatment group alone, and again adding FM and FFM to the model. The study was not 220 powered to detect differences among the 4 treatment groups for the exploratory 221 exercise intervention aim. Therefore, only descriptive statistics and within-group 222 changes are presented for the exercise and non-exercise groups within each drug 223 group. All analyses were done using SAS 9.3 (SAS Institute, Cary, NC). Data arereported as mean±SD or mean (95% CI), unless otherwise specified. The effects of theand 9 participants were lost to follow-up (personal reasons, 4; lack of time, 3; side 231 effects of GnRH AG , 1; hypertension; 1). Of the 70 women who completed the 232 intervention, 35 were randomized to GnRH AG +E 2 and 35 to GnRH AG +PL. Due to 233 scheduling limitations, not all subjects could be studied in the room calorimeter. Thus, 234 complete EE data for the current paper were obtained on 24 women in the GnRH AG +PL 235 group and 21 women in the GnRH AG +E 2 group. There were no significant differences in 236 the characteristics of the drug groups at baseline, except for testosterone, which was 237 higher in GnRH AG +PL (Table 1) . Following the 5-month intervention, serum E 2 was 238 decreased in GnRH AG +PL (-69.5±80.8 pg/mL, p<0.001) and increased in GnRH AG +E 2 239 (71.8±115.7 pg/mL, p=0.02, between-group difference in change over time, p<0.01). 240 investigate the regulation of EE by E 2 in a controlled manner in humans. Our results 296 demonstrated that chronic sex hormone suppression reduced REE, SEE, ExEE and 297 TEE, and that E 2 therapy attenuated the decreases in REE and ExEE. If our model of 298 pharmacologic suppression of ovarian function mimics the effects of menopause on 299 bioenergetics, the decreases in EE may contribute, at least in part, to the propensity for 300 fat gain across the menopause transition. 301
Suppression of sex hormones has been shown to cause increases in fat mass, 302
with a preferential accumulation of visceral adiposity (6, 8, 32, 44) . This fat 303 accumulation pattern is mirrored during the menopause (21, 28, 40). Furthermore, 304 several large randomized controlled trials (RCTs) have demonstrated that women on 305 hormone therapy (HT) gain less weight and fat mass then placebo-treated women (9, 306 15, 17, 36), and that the attenuated fat gain in women on HT is primarily from the trunk 307 region (11, 15, 18, 20) , suggesting a protective effect of estrogens. The results of the 308 current study did not confirm an effect of E 2 to protect against excess fat accumulation. 309
In fact, the GnRH AG +E 2 group had an increase in fat mass whereas the GnRH AG +PL 310 group did not. Based on previous studies of the effects of 16 to 24 weeks of GnRH AG 311 therapy on body composition (6, 7, 26, 32, 44) , the expected increase in fat mass after 312 20 weeks of GnRH AG +PL therapy was 1.0 to 1.5 kg; the change in this group was -0.2 313 kg. The previous studies of GnRH AG therapy did not evaluate the effects of adding back 314
gain. An alternative explanation for our findings is that, because weight gain was 320 discussed during the consenting process for the current study, it is possible that the 321 results were influenced by behavioral modifications. This may not have been the case 322 in previous studies because they involved patients undergoing GnRH AG therapy for a 323 clinical indication (e.g., treatment of endometriosis or uterine fibroids) (6, 7, 26, 32, 44) . 324
Several lines of evidence suggest that the decrease in endogenous E 2 is the 325 mechanistic trigger that disrupts energy balance and causes weight gain. For example, 326 replacing E 2 in rodents after OVX attenuates the weight and fat gain that occurs with 327 OVX (30, 42). Furthermore, disrupting E 2 signaling by knocking out estrogen receptor α 328 (ERα KO) causes excessive weight and fat gain (13, 27) . However, how lack of E 2 329 causes weight gain is not understood. There is strong preclinical evidence from studies 330 of OVX vs OVX+E 2 that lack of E 2 causes a decrease in TEE through reductions in 331 physical activity and resting metabolic rate (12, 25, 33, 41) . It has also been 332 demonstrated that EE is reduced when ERα signaling in hypothalamic steroidogenic 333 factor-1 (SF1) neurons is disrupted (43). Whether such effects of E 2 also occur in 334 humans is not well understood. In women, REE varies across the menstrual cycle and 335 is lowest during the early-follicular phase, when ovarian hormones are low (2, 5, 22, 23, 336 35). However, in these studies, it was not possible to isolate the potential effects of E 2 337 from other factors (e.g., progesterone). Our results are consistent with preclinicalstudies (33, 41, 43) and provide the first mechanistic evidence in women demonstratingunpublished data), and hypothesize that this reflects acclimation to sleeping in the 409 unfamiliar setting of the room calorimeter. If metabolic rate was, indeed, increased at 410 night in response to GnRH AG +PL because of sleep disruptions, this may explain why the 411 difference between the groups in the change in REE (-54 The decrease in ExEE in both groups was also unexpected, because weight 415 remained unchanged in GnRH AG +PL and slightly increased in GnRH AG +E 2 . The energy 416 cost of the exercise performed in this study (bench stepping) is determined by body 417 weight and stepping rate. Although the women were asked to match stepping cadence 418 to a metronome, whether this occurred was not verified. Further, we did not have an 419
objective measurement of whether they completed the entire prescribed bout of 420 exercise. Thus, it is possible that the decrease in ExEE was the result of decreases in 421 stepping rate and/or exercise time rather than to the suppression of sex hormones. 422 
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